个人科研网厅 | | 帮助
高级检索
当前位置： 首页 > 详情页

CAR T-cell treatment during the COVID-19 pandemic: Management strategies and challenges

| 认领 | 导出 | |

文献详情

资源类型：
WOS体系：
Pubmed体系：

收录情况： ◇ SCIE

作者：
Xu, Yongxian[1,2,3] * ; Su, Elaine Tan[1,2,3] ; Yang, Yingying[1,2,3] ; Wu, Hengwei[1,2,3] ; Wei, Guoqing[1,2,3] ; Su, Junwei[4] ; Cui, Qu[5] ; Jin, Aiyun[1,2,3] ; Yang, Li[1,2,3] ; Fu, Shan[1,2,3] ; Zhou, Jianfeng[6] ; Qiu, Lugui[7,8,9] ; Zhang, Xi[10] ; Liang, Aibin[11] ; Jing, Hongmei[12] ; Li, Yuhua[13] ; Blaise, Didier[14] ; Mohty, Mohamad[15,16] ; Nagler, Arnon[17] ; Huang, He[1,2,3] ;
单位： [1]Zhejiang Univ, Affiliated Hosp 1, Bone Marrow Transplantat Ctr, Sch Med, 79 Qingchun Rd, Hangzhou, Peoples R China [2]Zhejiang Prov Engn Lab Stem Cell & Immun Therapy, Hangzhou, Peoples R China [3]Zhejiang Univ, Inst Hematol, Hangzhou, Peoples R China [4]Zhejiang Univ, Collaborat Innovat Ctr Diag & Treatment Infect Di, State Key Lab Diag & Treatment Infect Dis,Affliat, Natl Clin Res Ctr Infect Dis,Dept Infect Dis, Hangzhou, Zhejiang, Peoples R China [5]Capital Med Univ, Beijing Tiantan Hosp, Dept Hematol, Beijing, Peoples R China [6]Huazhong Univ Sci & Technol, Dept Hematol, Tongji Hosp, Tongji Med Coll, Wuhan, Peoples R China [7]Chinese Acad Med Sci, Inst Hematol, State Key Lab Expt Hematol, Tianjin, Peoples R China [8]Chinese Acad Med Sci, Blood Dis Hosp, Tianjin, Peoples R China [9]Peking Union Med Coll, Tianjin, Peoples R China [10]Army Med Univ, Xinqiao Hosp, Med Ctr Hematol, Chongqing, Peoples R China [11]Shanghai Tongji Hosp, Dept Hematol, Shanghai, Peoples R China [12]Peking Univ Third Hosp, Dept Hematol, Beijing, Peoples R China [13]Southern Med Univ, Dept Hematol, Zhujiang Hosp, Guangzhou, Peoples R China [14]Aix Marseille Univ, Transplant & Cellular Immunotherapy Programs, Dept Hematol, CNRS,INSERM,CRCM,Inst Paoli Calmettes, Marseille, France [15]Sorbonne Univ, Dept Hematol, Hop St Antoine, Paris, France [16]CEREST TC, INSERM, EBMT Paris Study Off, UMRs 938, Paris, France [17]Chaim Sheba Med Ctr, Hematol & Bone Marrow Transplantat Div, Tel Hashomer, Israel
出处：
DOI： 10.1016/j.retram.2020.06.003
ISSN：

关键词： Chimeric antigen receptor T-cells COVID-19 Relapsed/refractory hematological malignancies Immunocompromised Cytokine release syndrome

摘要：
The pandemic of coronavirus disease 2019 (COVID-19), which is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is spreading rapidly across the world. Currently, the COVID-19 pandemic is affecting the continuity of essential routine healthcare services and procedures, including chimeric antigen receptor T-cell (CAR-T) therapy, a life-saving option for patients with relapsed/refractory (R/R) hematologic malignancies. Due to the rapid disease progression of hematological malignancies, there is an urgent need to manufacture and utilize CAR T-cells. However, CAR-T treatment has become extraordinarily challenging during this COVID-19 pandemic. Thus, many medical and technical factors must now be taken into consideration before, during, and after CAR-T therapy. The purpose of this review is to provide brief suggestions for rational decision-making strategies in evaluating and selecting CAR T-cell treatment and appropriate CAR T-cell products, and protective strategies for medical staff and patients to prevent infection in the midst of the current COVID-19 pandemic. (C) 2020 Published by Elsevier Masson SAS.

基金：
Natural Science Foundation of China [81770201, 81730008]; Key Project of Science and Technology Department of Zhejiang Province [2018C03016-2]

基金编号： 81770201 81730008 2018C03016-2

语种：
外文
被引次数：
WOS：
PubmedID：
中科院(CAS)分区：
出版当年[2019]版：
大类 | 4 区 医学
小类 | 4 区 医学：研究与实验
最新[2025]版：
大类 | 4 区 医学
小类 | 4 区 医学：研究与实验
JCR分区：
出版当年[2018]版：
Q3 MEDICINE, RESEARCH & EXPERIMENTAL
最新[2023]版：
Q2 MEDICINE, RESEARCH & EXPERIMENTAL

影响因子： 最新[2023版] 最新五年平均 出版当年[2018版] 出版当年五年平均 出版前一年[2017版] 出版后一年[2019版]

第一作者：
第一作者单位： [1]Zhejiang Univ, Affiliated Hosp 1, Bone Marrow Transplantat Ctr, Sch Med, 79 Qingchun Rd, Hangzhou, Peoples R China [2]Zhejiang Prov Engn Lab Stem Cell & Immun Therapy, Hangzhou, Peoples R China [3]Zhejiang Univ, Inst Hematol, Hangzhou, Peoples R China
通讯作者：
通讯机构： [1]Zhejiang Univ, Affiliated Hosp 1, Bone Marrow Transplantat Ctr, Sch Med, 79 Qingchun Rd, Hangzhou, Peoples R China [2]Zhejiang Prov Engn Lab Stem Cell & Immun Therapy, Hangzhou, Peoples R China [3]Zhejiang Univ, Inst Hematol, Hangzhou, Peoples R China
推荐引用方式(GB/T 7714)：
Xu Yongxian,Su Elaine Tan,Yang Yingying,et al.CAR T-cell treatment during the COVID-19 pandemic: Management strategies and challenges[J].CURRENT RESEARCH IN TRANSLATIONAL MEDICINE.2020,68(3):111-118.doi:10.1016/j.retram.2020.06.003.
APA：
Xu, Yongxian,Su, Elaine Tan,Yang, Yingying,Wu, Hengwei,Wei, Guoqing...&Huang, He.(2020).CAR T-cell treatment during the COVID-19 pandemic: Management strategies and challenges.CURRENT RESEARCH IN TRANSLATIONAL MEDICINE,68,(3)
MLA：
Xu, Yongxian,et al."CAR T-cell treatment during the COVID-19 pandemic: Management strategies and challenges".CURRENT RESEARCH IN TRANSLATIONAL MEDICINE 68..3(2020):111-118

相关文献

[1]CD19嵌合抗原受体T细胞治疗后细胞因子释放综合征的诊治进展 [2]Fueling chimeric antigen receptor T cells with cytokines [3]Tocilizumab vs CRRT in Management of Cytokine Release Syndrome (CRS) in COVID-19 [4]A Reversible Chemogenetic Switch for Chimeric Antigen Receptor T Cells** [5]A Reversible Chemogenetic Switch for Chimeric Antigen Receptor T Cells. [6]Targeting JAK-STAT Signaling to Control Cytokine Release Syndrome in COVID-19 [7]Tocilizumab: The Key to Stop Coronavirus Disease 2019 (COVID-19)-Induced Cytokine Release Syndrome (CRS)? [8]Tumor-derived extracellular vesicles induce invalid cytokine release and exhaustion of CD19 CAR-T Cells [9]嵌合抗原受体的T细胞免疫疗法治疗B淋巴细胞血液恶性肿瘤的护理 [10]Chimeric antigen receptor T cells: a novel therapy for solid tumors

资源点击量：426 今日访问量：0 总访问量：410 更新日期：2025-04-01 建议使用谷歌、火狐浏览器 常见问题

版权所有：重庆聚合科技有限公司 渝ICP备12007440号-3 地址：重庆市两江新区泰山大道西段8号坤恩国际商务中心16层（401121）